December 2022 - Volume 81 - 12

HEROES AND PILLARS OF RHEUMATOLOGY

1. EULAR 75-year anniversary: commentaries on ARD papers from 25 years ago

RECOMMENDATIONS

2. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update 

3. EULAR points to consider for minimal reporting requirements in synovial tissue research in rheumatology

CRITERIA

4. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis 

5. 2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis 

RHEUMATOID ARTHRITIS

6. Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study 

7. Stage-specific roles of microbial dysbiosis and metabolic disorders in rheumatoid arthritis 

SPONDYLOARTHRITIS

8. Isolated axial disease in psoriatic arthritis and ankylosing spondylitis with psoriasis 

SYSTEMIC LUPUS ERYTHEMATOSUS

9. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial 

10. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α 

11. Dissecting the histological features of lupus nephritis highlights new common patterns of injury in class III/IV 

12. Loss-of-function variants in SAT1 cause X-linked childhood-onset systemic lupus erythematosus

SYSTEMIC SCLEROSIS

13. Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON 

AUTOINFLAMMATORY DISORDERS

14. Distinct immune-effector and metabolic profile of CD8+ T cells in patients with autoimmune polyarthritis induced by therapy with immune checkpoint inhibitors

EPIDEMIOLOGY

15. Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave 

16. Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study 

17. Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases 

EULAR NEWS

18. News from EULAR 

LETTERS

19. Serum urate outcomes of treat-to-target urate lowering treatment: results of a nationwide cohort study from 1997 to the COVID-19 pandemic using data from the Clinical Practice Research Datalink 

20. Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study 

ELECTRONIC PAGES

21. Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ 

22. Response to: ‘Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Ventura et al’ 

23. Correspondence on ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’ 

24. Response to: ‘Correspondence on ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’’ by Jeny et al 

25. Correspondence to ‘Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases’ 

26. Response to: ‘Correspondence to ‘Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases’’ by Wu et al 

27. No increased rate of SARS-CoV-2 infection for patients with inflammatory rheumatic diseases compared with the general population in the city of Hamburg (Germany) 

28. Correspondence on ‘Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis’ 

29. Response to: ‘Correspondence on ‘Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis’’ by Xu 

30. Correspondence on ‘EULAR recommendations for the management of antiphospholipid syndrome in adults’ 

31. Response to: ‘Correspondence on ‘EULAR recommendations for the management of antiphospholipid syndrome in adults’ by Zhou et al 

32. Correspondence on ‘Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial’ 

33. Response to: ‘Correspondence on ‘Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial’’ by Bredemeier 

34. Correspondence on ‘Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence’ 

35. Response to ‘Correspondence on “Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence” by Zhang et al 

36. Correspondence to ‘Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression’ 

37. Response to: ‘Correspondence to ‘Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression’’ by Wang and Ma 

38. Correspondence on ‘Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial’ 

39. Response to: ‘Correspondence on ‘Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial’’ by Satis et al 

40. Correspondence on ‘Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells’ 

41. Response to ‘Correspondence on ‘Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells’’ by Wang and Niu 

42. Role of interaction between B cells and epithelial cells in pSS 

43. Response to: ‘Role of interaction between B cells and epithelial cells in pSS’ by Pringle et al 

44. Elucidation of disease mechanisms underlying rheumatic immune-related adverse events may lead to novel therapeutic strategies for autoimmune diseases 

45. Management of immune checkpoint inhibitor-induced polymyalgia rheumatica 

ISSUE INFORMATION